Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An announcement from GH Research ( (GHRS) ) is now available.
On May 14, 2026, GH Research PLC entered into an at-the-market equity offering sales agreement with Stifel, Nicolaus & Company to sell up to $200 million of its ordinary shares from time to time. The shares are registered under an existing Form F-3 shelf registration, with a related prospectus supplement filed the same day, giving the company flexible access to incremental equity capital that could bolster its balance sheet and fund ongoing operations while potentially diluting existing shareholders over time.
The company also confirmed that this Form 6-K and the underlying sales agreement, legal opinion and related consents are incorporated by reference into several of its existing Form S-8 and Form F-3 registration statements. This cross-referencing streamlines future securities issuances under those registrations, reinforcing GH Research’s ability to tap equity markets efficiently as financing needs arise.
The most recent analyst rating on (GHRS) stock is a Buy with a $32.00 price target. To see the full list of analyst forecasts on GH Research stock, see the GHRS Stock Forecast page.
Spark’s Take on GHRS Stock
According to Spark, TipRanks’ AI Analyst, GHRS is a Neutral.
The score is held back primarily by weak financial performance (no revenue, widening losses, and ongoing cash burn), partly offset by a strong, low-leverage balance sheet. Technicals are supportive with clear upward trend and positive momentum, while valuation remains a drag due to negative earnings and no dividend.
To see Spark’s full report on GHRS stock, click here.
More about GH Research
GH Research PLC is an Ireland-incorporated foreign private issuer listed in the United States, operating in the biopharmaceutical sector and focused on developing innovative therapies. The company accesses U.S. capital markets through SEC-registered equity offerings to support its research pipeline and broader corporate initiatives.
Average Trading Volume: 216,444
Technical Sentiment Signal: Buy
Current Market Cap: $1.48B
See more insights into GHRS stock on TipRanks’ Stock Analysis page.